119 results on '"Czajka, Hanna"'
Search Results
2. Vaccination Against Measles, Mumps, and Rubella in the Light of Current Epidemic Threats: Unjustified Postponement
3. Rotavirus Vaccination of Premature Newborns in the NICU: Evaluation of Vaccination Rates and Safety Based on a Single-Centre Study
4. One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life
5. A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinations
6. New Insights on Respiratory Syncytial Virus Prevention.
7. Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age
8. Trained Immunity, BCG and SARS-CoV-2 General Outline and Possible Management in COVID-19
9. A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Impact of BCG Re-Vaccination on the Incidence and Severity of SARS-CoV-2 Infections among Symptomatic Healthcare Professionals during the COVID-19 Pandemic in Poland—Evaluation of Antibody Concentrations
10. Newborn screening and gene therapy in SMA: Challenges related to vaccinations
11. Circulating Antibody 1 and 2 Years After Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine in Preterm Compared With Term Infants
12. A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Impact of BCG Re-Vaccination on the Incidence and Severity of SARS-CoV-2 Infections among Symptomatic Healthcare Professionals during the COVID-19 Pandemic in Poland—Evaluation of Antibody Concentrations
13. A Multi-Center, Randomised, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Impact of BCG Re-Vaccination on the Incidence and Severity of SARS-CoV-2 Infections among Symptomatic Healthcare Professionals during the COVID-19 Pandemic in Poland—First Results
14. Recommendations of the Polish Paediatric Society, the Polish Society of Vaccinology, and the Polish Society of Family Medicine on meningococcal vaccinations in children and adults in Poland
15. A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults
16. Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries
17. Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the introduction of HPV vaccines
18. 6. Pentavalent Meningococcal (MenABCWY) Vaccine is Safe and Well Tolerated With Immunogenicity Noninferior to Coadministered MenB-FHbp and MenACWY-CRM in a Phase 2 Study of Healthy Adolescents and Young Adults
19. Who or What Influences the Individuals’ Decision-Making Process Regarding Vaccinations?
20. Recommendations of the Polish Paediatric Society and the National Consultant in the field of paediatrics regarding outpatient care for children during the COVID-19 pandemic caused by SARS-CoV-2
21. Corrigendum to “One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life” [Vaccine 36 (2018) 381–387]
22. Recommendations of the Polish Paediatric Society and the National Consultant in the field of paediatrics regarding outpatient care for children during the COVID-19 pandemic caused by SARS-CoV-2.
23. Implementation of mandatory vaccinations against diphtheria, tetanus and pertussis in preterm infants as part of the Polish Immunization Programme
24. DLACZEGO SZCZEPIENIA OCHRONNE SĄ NADAL POTRZEBNE?
25. 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Preterm Versus Term Infants
26. Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Manufactured With and Without Polysorbate 80 Given to Healthy Infants at 2, 3, 4 and 12 Months of Age
27. Why should we revaccinate children after stem cell transplantations?
28. Rekomendacje zespołu ekspertów dotyczące stosowania dwudawkowego schematu szczepień przeciw ospie wietrznej
29. A Randomized, Controlled Trial to Assess the Immunogenicity and Safety of a Heptavalent Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, Hib and Meningococcal Serogroup C Combination Vaccine Administered at 2, 3, 4 and 12–18 Months of Age
30. Erratum to “A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra™): Immunogenicity and safety profile” by Czajka et al. [Vaccine 27 (47) (2009) 6504–6511]
31. Szczepienie dzieci przedwcześnie urodzonych oraz z małą urodzeniową masą ciała
32. Aktualne zasady stosowania pediatrycznych szczepionek wysoce skojarzonych zawierających komponentę bezkomórkową przeciw krztuścowi (DTPa) u niemowląt i dzieci do 3. roku życia
33. Corrigendum to “A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra 〈trade〉): Immunogenicity and safety profile” Vaccine 27 (2009) 6504–6511
34. Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children
35. A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra™): Immunogenicity and safety profile
36. Immunogenicity of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the Licensed 7vCRM Vaccine
37. A New Combination Haemophilus influenzae Type B and Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine for Primary Immunization of Infants
38. VACCINATION OF PRETERM INFANTS BY POLYVALENT VACCINES: IMMUNOGENICITY AND SAFETY - REVIEW OF LITERATURE.
39. Immunogenicity of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzaeProtein D Conjugate Vaccine (PHiD-CV) Compared to the Licensed 7vCRM Vaccine
40. A New Combination Haemophilus influenzaeType B and Neisseria meningitidisSerogroup C-Tetanus Toxoid Conjugate Vaccine for Primary Immunization of Infants
41. [Why are preventive vaccinations still required?]
42. Status of immunity for vaccine--preventable diseases in children after hematopoietic stem cells transplantation.
43. [Safety and efficacy of vaccination in children after stem cell transplantation. Part 1].
44. [What is parents' and medical health care specialists knowledge about vaccinations?].
45. [Controversies around vaccinations].
46. [Paediatric Expert Group on the Immunization Programme. Activities focusing on effective immunization in Poland].
47. [Immunization in preterm infants--current knowledge].
48. [Why should we revaccinate children after stem cell transplantations?].
49. [Hypotonic-hyporesponsive episode (HHE) following vaccination with a combined vaccine against diphtheria, tetanus and pertussis (whole cell vaccine -DTPv)].
50. [Vaccinations as a cause of children hospitalisation in Neuroinfection Department of the John Paul II Hospital in Cracow between 2002--2004].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.